Kura Oncology (NASDAQ:KURA) Reaches New 52-Week Low – What’s Next?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) reached a new 52-week low on Monday . The stock traded as low as $7.07 and last traded at $7.10, with a volume of 78892 shares. The stock had previously closed at $7.32.

Analyst Ratings Changes

A number of research analysts have recently issued reports on KURA shares. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Up 0.3 %

The company’s 50-day simple moving average is $11.14 and its two-hundred day simple moving average is $16.61. The firm has a market capitalization of $564.57 million, a P/E ratio of -3.08 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd purchased a new stake in Kura Oncology in the 3rd quarter worth approximately $146,000. Quarry LP bought a new stake in Kura Oncology during the 2nd quarter worth approximately $196,000. Erste Asset Management GmbH purchased a new position in Kura Oncology during the third quarter valued at approximately $215,000. Finally, Bellevue Group AG boosted its position in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.